Multiomics Services Market Report: Market Size & Forecast 2026

The global multiomics services market covers outsourced and platform-based solutions that combine two or more omics disciplines, genomics, transcriptomics, proteomics, and metabolomics, into unified analytical workflows. After reaching approximately $2.76 billion in 2024 and $3.18 billion in 2025, the market is assessed at roughly $2.86 to 3.57 billion in 2026, with forecast trajectories pointing toward $10.56 billion by 2034 and as high as $13.20 billion by 2035 depending on source methodology.

• •Market size in 2026 estimated between $2.86 billion and $3.57 billion across multiple industry sources
• •Projected to reach $10.56-13.20 billion by 2034-2035, implying long-term CAGR near 16%
• •Encompasses instrument-based and consumable-based offerings across genomics, transcriptomics, proteomics, and metabolomics platforms

A central engine of growth is the rapid diffusion of single-cell sequencing and spatial multiomics technologies, which generate far richer biological datasets than traditional bulk approaches and drive outsourced service demand. Oncology remains the dominant application area, with multiomics profiling increasingly embedded in precision medicine programs and clinical trial design. Expanding biopharmaceutical R&D budgets, coupled with public-sector investments in large-scale population genomics initiatives, sustain robust demand across academic, clinical, and commercial end users.

• •Single-cell and spatial multiomics adoption accelerating as researchers seek higher-resolution cellular and molecular insights
• •Oncology and immunology applications driving the largest share of service demand in drug discovery and biomarker development
• •Rising R&D expenditure by pharmaceutical and biotechnology firms and government-funded population-scale genomics programs expanding the addressable market

The market is segmented by offering into products, instruments and consumables, and services, with instruments representing the larger product sub-segment and consumables generating recurring high-margin revenue. By technology approach, single-cell multiomics is growing faster than bulk analysis due to its superior resolution for heterogeneous tissue and rare-cell studies. Geographically, North America holds the largest share, supported by dense biopharmaceutical infrastructure and major research institutions, while Europe and the Asia-Pacific region are expanding rapidly through increased life-sciences investment and growing domestic capabilities.

• •Product offerings split into instruments and consumables; services segment growing in parallel as outsourcing becomes standard practice
• •Single-cell approach outpacing bulk analysis due to demand for high-resolution cellular profiling in oncology, immunology, and neuroscience
• •North America leads in market share, with Europe and Asia-Pacific as the fastest-growing regions driven by R&D expansion and healthcare infrastructure investment

Who are the notable companies in the industry?

The market exhibits a mixed competitive structure with both fully integrated life-sciences conglomerates offering broad instrument and reagent portfolios and a significant population of specialized service providers focused on niche omics or application areas. Integration depth varies: some participants control the full stack from proprietary instrument platforms through consumables to cloud-based data analytics, while others concentrate on sequencing or informatics layers. Capacity concentration is highest in North America and Western Europe, where major instrument manufacturing and leading contract research organizations are headquartered, though Asia-Pacific capacity is expanding as regional providers scale domestic service offerings.

• •Competitive structure is moderately fragmented with a mix of broad integrated platform providers and specialized niche service operators
• •Technology routes span DNA sequencing, mass spectrometry, and microfluidic-based platforms, with integrated offerings extending into bioinformatics and data interpretation services
• •Manufacturing and service capacity concentrated in North America and Europe, with Asia-Pacific capacity growing rapidly as regional suppliers and contract research providers expand

What are the recent trends and outlook?

Artificial intelligence and machine learning are increasingly embedded in multiomics data pipelines, enabling automated pattern recognition across combined omics layers and accelerating translational research outputs. Spatial transcriptomics and multi-omic integration at the single-cell level represent the next frontier, with both academic and commercial pipelines investing heavily in platforms that preserve spatial context alongside molecular profiles. Long-term market growth is underpinned by the convergence of multiomics with clinical diagnostics, personalized medicine programs, and digital biology initiatives that demand increasingly sophisticated, high-throughput multi-layered analytical capabilities through 2035 and beyond.

• •AI-driven bioinformatics and machine learning pipelines being integrated into multiomics platforms to automate cross-omics data analysis and interpretation
• •Spatial multiomics and single-cell multi-omic integration emerging as high-priority investment areas for both instrument developers and service providers
• •Convergence with clinical diagnostics and precision medicine expected to expand the market beyond pure research into regulated therapeutic and companion-diagnostic applications by the early 2030s